JWH-133

**JWH‑133** is a synthetic cannabinoid belonging to the dibenzopyran class. It is structurally related to delta(9)-tetrahydrocannabinol (THC) but lacks the hydroxy group at the C1 position and features a 1,1-dimethylbutyl group at position 3. JWH‑133 acts as a highly potent and selective agonist of the cannabinoid receptor type 2 (CB2), with over 200-fold selectivity for CB2 over CB1 receptors (Ki = 3.4 nM for CB2; Ki = 677 nM for CB1)[2][3][5]. Its mechanism of action involves activation of CB2 receptors leading to anti-inflammatory effects by preventing microglial activation and reducing neuroinflammation[2]. Preclinical studies have shown that it can reduce spasticity in models of multiple sclerosis[4][5], suppress inflammation in experimental colitis and pancreatitis[5], inhibit tumor growth via increased apoptosis and impaired angiogenesis[5], and may have neuroprotective effects relevant to Alzheimer's disease by preventing amyloid beta-induced inflammation[2]. Discovered by John W. Huffman.

Other names

(6aR,10aR)-3-(1,1-dimethylbutyl)-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran3-(1,1-dimethylbutyl)-6aR,7,10,10aR-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyranDimethylbutyl-deoxy-delta(8)-THC